AlzeCure Pharma AB (OSTO:ALZCUR) Pre-Tax Income : kr-35.66 Mil (TTM As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is AlzeCure Pharma AB Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. AlzeCure Pharma AB's pretax income for the three months ended in Sep. 2024 was kr-7.45 Mil. Its pretax income for the trailing twelve months (TTM) ended in Sep. 2024 was kr-35.66 Mil. AlzeCure Pharma AB's pretax margin was %.

AlzeCure Pharma AB Pre-Tax Income Historical Data

The historical data trend for AlzeCure Pharma AB's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AlzeCure Pharma AB Pre-Tax Income Chart

AlzeCure Pharma AB Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Pre-Tax Income

Get a 7-Day Free Trial

-50.86

-71.37

-77.78

-56.24

-37.17

AlzeCure Pharma AB Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Pre-Tax Income	Get a 7-Day Free Trial															-7.66	-9.76	-9.80	-8.65	-7.45

Competitive Comparison of AlzeCure Pharma AB's Pre-Tax Income

For the Biotechnology subindustry, AlzeCure Pharma AB's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AlzeCure Pharma AB's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AlzeCure Pharma AB's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where AlzeCure Pharma AB's Pre-Tax Income falls into.

AlzeCure Pharma AB Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

AlzeCure Pharma AB's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-38.344	+	0	+	-0.007	+	1.102	+	0.082000000000001
	=	-37.17

AlzeCure Pharma AB's Pretax Income for the quarter that ended in Sep. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-7.804	+	0	+	0	+	0.357	+	0
	=	-7.45

Pre-Tax Income for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-35.66 Mil.

AlzeCure Pharma AB (OSTO:ALZCUR) Pre-Tax Income Explanation

AlzeCure Pharma AB's Pretax Margin for the quarter that ended in Sep. 2024 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-7.447	/	0
	=	%

AlzeCure Pharma AB Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of AlzeCure Pharma AB's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

AlzeCure Pharma AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AlzeCure Pharma AB (OSTO:ALZCUR) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

AC6:Germany

Address

Halsovagen 7, Huddinge, SWE, SE 141 57

Website

https://www.alzecurepharma.se

AlzeCure Pharma AB is a Swedish pharmaceutical company engaged in drug research with a primary focus on Alzheimer's disease. The company develops several drugs within its three research platforms NeuroRestore, Alzstatin, and Painless. The company's drug candidates include; ACD440, which is in the clinical development phase for the treatment of neuropathic pain, ACD856, ACD857, ACD679, and ACD680 for the treatment of Alzheimer's disease, and ACD137 for the treatment of severe pain in conditions such as osteoarthritis.

AlzeCure Pharma AB Headlines

No Headlines